Genmab
Open
$26.53
Prev. Close
$26.53
High
$26.53
Low
$26.52
Market Snapshot
$16.76B
17.4
1.77
$3.12B
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
emptyResult
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Recently from Cashu
Genmab schedules Feb. 17 Q4 report as forum for pipeline and partnership updates
Genmab pins Q4 disclosure to Feb. 17 as forum for pipeline and partnership updates Main development: Q4 earnings call becomes focal point for clinical and commercial progress Genmab schedules its four…
Genmab Partners with Anthropic to Transform Drug Discovery Using AI Innovations
Genmab Partners with Anthropic to Accelerate Drug Discovery Through AI Innovation Genmab, a leading biotechnology company, enters a strategic partnership with the artificial intelligence firm Anthropi…
Genmab’s Tafasitamab: A Potential Breakthrough in DLBCL Treatment Following Incyte Trial Results
Incyte's Groundbreaking Trial Results Signal a New Era in DLBCL Treatment Incyte Corporation announces compelling topline results from its pivotal Phase 3 frontMIND trial, showcasing the effectiveness…
Genmab's Tafasitamab Shows Promise as First-Line DLBCL Treatment in Incyte's Phase 3 Trial
Incyte's Promising Advances in DLBCL Treatment Incyte Corporation recently announces the topline results from its pivotal Phase 3 frontMIND trial, focusing on the efficacy of tafasitamab (Monjuvi/Minj…